GNRH1 and Laron syndrome: Of patients with Laron syndrome, 15.8% received at least 1 concomitant dose of gonadotropin-releasing hormone (GnRH) agonist; 5.9% and 2.2% of patients in the overall and NPP populations received at least 1 concomitant dose of GnRH agonist treatment.